Abstract
Neonatal sepsis remains a feared cause of morbidity and mortality in the neonatal period. Maternal, neonatal, and environmental factors are associated with risk of infection, and a combination of prevention strategies, judicious neonatal evaluation, and early initiation of therapy are required to prevent adverse outcomes. This article reviews recent trends in epidemiology and provides an update on risk factors, diagnostic methods, and management of neonatal sepsis.
Copyright © 2013 Elsevier Inc. All rights reserved.
MeSH terms
-
Adaptive Immunity
-
Anti-Infective Agents / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage
-
Antifungal Agents / administration & dosage
-
Bacterial Infections / complications
-
Biomarkers / blood*
-
Blood Cell Count
-
C-Reactive Protein / metabolism
-
Candidiasis / complications
-
Escherichia coli Infections / complications*
-
Escherichia coli Infections / immunology
-
Fluconazole / administration & dosage
-
Genomics
-
Humans
-
Immunity, Innate
-
Immunoglobulins, Intravenous / administration & dosage
-
Infant, Newborn
-
Infant, Newborn, Diseases / blood
-
Infant, Newborn, Diseases / drug therapy*
-
Infant, Newborn, Diseases / epidemiology
-
Infant, Newborn, Diseases / immunology
-
Infant, Newborn, Diseases / microbiology*
-
Lactoferrin / administration & dosage
-
Polymerase Chain Reaction
-
Predictive Value of Tests
-
Proteomics
-
Risk Factors
-
Sepsis / blood
-
Sepsis / drug therapy*
-
Sepsis / epidemiology
-
Sepsis / immunology
-
Sepsis / microbiology*
-
Sepsis / prevention & control
-
Streptococcal Infections / complications*
-
Streptococcal Infections / immunology
-
Streptococcus agalactiae* / immunology
-
Streptococcus agalactiae* / isolation & purification
Substances
-
Anti-Infective Agents
-
Antibodies, Monoclonal
-
Antifungal Agents
-
Biomarkers
-
Immunoglobulins, Intravenous
-
Fluconazole
-
C-Reactive Protein
-
Lactoferrin